Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2019.16326
Abstract: This cohort study describes patterns of development, management strategies, and long-term vascular consequences of hypertension associated with ibrutinib in the non–clinical trial setting. read more here.
Keywords: hypertension patients; patients treated; ibrutinib chronic; treated ibrutinib ... See more keywords
Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib‐resistant chronic lymphocytic leukaemia
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13281
Abstract: Ibrutinib exerts promising anticancer effects in chronic lymphocytic leukaemia (CLL). However, acquired resistance occurs during treatment, necessitating the exploration of underlying mechanisms. Although three‐dimensional genome organization has been identified as a major player in the… read more here.
Keywords: pak1; ibrutinib resistant; chronic lymphocytic; chromosome conformation ... See more keywords
Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24779
Abstract: [1] Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90: 831–841. [2] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification… read more here.
Keywords: myelodysplastic syndromes; brazil retrospective; lymphocytic leukemia; leukemia brazil ... See more keywords
A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25614
Abstract: 1. Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131. 2. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Imbruvica NDA… read more here.
Keywords: lymphocytic leukemia; lymphohistiocytosis; hemophagocytic lymphohistiocytosis; chronic lymphocytic ... See more keywords
Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise: A nationwide population‐based study
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25681
Abstract: Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise : a nationwide population-based study read more here.
Keywords: leukemia estimated; lymphocytic leukemia; estimated future; prevalence chronic ... See more keywords
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26502
Abstract: apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA. 2021;326(23):2395-2404. 3. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment… read more here.
Keywords: hematology; chronic lymphocytic; outcomes chronic; lymphocytic leukemia ... See more keywords
Management of front line chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26677
Abstract: Treatment options with targeted agents have changed the treatment landscape of CLL profoundly. Besides chemoimmunotherapy, treatment regimen approved for frontline therapy include continuous treatment with BTK inhibitors like ibrutinib and acalabrutinib or fixed‐duration regimen like… read more here.
Keywords: front line; lymphocytic leukemia; chronic lymphocytic; management front ... See more keywords
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26826
Abstract: Orelabrutinib is a novel, small molecule, selective irreversible Bruton's tyrosine kinase inhibitor. The aim of this study was to evaluate the efficacy and safety in patients with refractory or relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic… read more here.
Keywords: lymphocytic leukemia; orelabrutinib; small lymphocytic; chronic lymphocytic ... See more keywords
Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2268
Abstract: Contemporary data describing treatment patterns, adverse events (AEs), and outcomes in patients with chronic lymphocytic leukemia (CLL) in clinical practice are lacking. We conducted a retrospective cohort study and assessed treatment patterns, AEs, health‐care resource… read more here.
Keywords: treatment; patterns adverse; patients chronic; adverse events ... See more keywords
98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2788
Abstract: Immunoglobulin heavy chain variable region (IGHV) mutational status has been an important prognostic factor for chronic lymphocytic leukemia (CLL) for decades. Patients with unmutated IGHV (≥98% identity to the germline sequence) have inferior prognosis and… read more here.
Keywords: prognosis; ighv identity; ighv; chronic lymphocytic ... See more keywords
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3470
Abstract: Limited information is available on the efficacy of front‐line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real‐world patients and performed… read more here.
Keywords: real world; ibrutinib; lymphocytic leukemia; bendamustine rituximab ... See more keywords